Clearview GLP1 Winners and Losers April 2024

GLP-1 receptor agonists are already reshaping people and healthcare systems for the management of obesity.  Treatment paradigms in cardiovascular disease, sleep apnea and MASH are set to be disrupted, but it is not all gravy; weight loss post GLP-1s is often not maintained and not everyone can tolerate their side effects. We share our perspectives on the outlook for the space, including some of the implications for biopharma, service providers and investors.”

                                                              Click here to Download